title: Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5-year outcomes.
abstract: BACKGROUND
  To evaluate the outcomes of nasopharyngeal carcinoma (NPC) patients treated with helical tomotherapy (HT).
  
  
  METHODS
  Between September 2007 and August 2012, 190 newly diagnosed NPC patients were treated with HT. Thirty-one patients were treated with radiation therapy as single modality, 129 with additional cisplatin-based chemotherapy with or without anti-EGFR monoclonal antibody therapy, and 30 with concurrent anti-EGFR monoclonal antibody therapy.
  
  
  RESULTS
  Acute radiation related side effects were mainly grade 1 or 2. Grade 3 and greater toxicities were rarely noted. The median followup was 32 (3-38) months. The local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were 96.1%, 98.2%, 92.0%, and 86.3%, respectively, at 3 years. Cox multivariate regression analysis showed that age and T stage were independent predictors for 3-year OS.
  
  
  CONCLUSIONS
  Helical tomotherapy for NPC patients achieved excellent 3-year locoregional control, distant metastasis-free survival, and overall survival, with relatively minor acute and late toxicities. Age and T stage were the main prognosis factors.
authors.affiliation: Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China ; Department of Radiation Oncology, Hainan Branch of Chinese PLA General Hospital, Haitang Bay, Sanya 572000, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Du
authors.affiliation: Department of Otorhinolaryngology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors.forename: Xin-Xin
authors.initials: XX
authors.lastname: Zhang
authors.affiliation: Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China ; Department of Radiation Oncology, Hainan Branch of Chinese PLA General Hospital, Haitang Bay, Sanya 572000, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China ; Department of Radiation Oncology, Hainan Branch of Chinese PLA General Hospital, Haitang Bay, Sanya 572000, China.
authors.forename: Lin-Chun
authors.initials: LC
authors.lastname: Feng
authors.affiliation: Department of Medical Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors.forename: Gui-Xia
authors.initials: GX
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors.forename: Bao-Lin
authors.initials: BL
authors.lastname: Qu
authors.affiliation: Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors.forename: Shou-Ping
authors.initials: SP
authors.lastname: Xu
authors.affiliation: Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors.forename: Chuan-Bin
authors.initials: CB
authors.lastname: Xie
authors.affiliation: Department of Radiation Oncology, Monmouth Medical Center, 300 2nd Avenue, Long Branch, NJ 07740, USA.
authors.forename: Jack
authors.initials: J
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma; D002648:Child; D002681:China / Q000453:epidemiology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000532:radiotherapy*; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects* / Q000379:methods*; D016019:Survival Analysis; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents